EGFR and non-small cell lung carcinoma: The anaplastic lymphoma kinase (ALK) gene fusion accounts for about 3%–6% of NSCLC, which is the second most commonly identified targeted driver gene after epidermal growth factor receptor (EGFR) mutations in NSCLC (Yu et al., 2016).